Literature DB >> 11369802

Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice.

M Kawashiri 1, Y Zhang, D Usher, M Reilly, E Puré, D J Rader.   

Abstract

The low density lipoprotein receptor (LDLR) plays a major role in regulation of plasma cholesterol levels as a ligand for apolipoprotein B-100 and apolipoprotein E (apoE). Consequently, LDLR-deficient mice fed a Western-type diet develop significant hypercholesterolemia and atherosclerosis. ApoE not only mediates uptake of atherogenic lipoproteins via the LDLR and other cell-surface receptors, but also directly inhibits atherosclerosis. In this study, we examined the hypothesis that coexpression of the LDLR and apoE would have greater effects than either one alone on plasma cholesterol levels and the development of atherosclerosis in LDLR-deficient mice. LDLR-deficient mice fed a Western-type diet for 10 weeks were injected with recombinant adenoviral vectors encoding the genes for human LDLR, human apoE3, both LDLR and apoE3, or lacZ (control). Plasma lipids were analyzed at several time points after vector injection. Six weeks after injection, mice were analyzed for extent of atherosclerosis by two independent methods. As expected, LDLR expression alone induced a significant reduction in plasma cholesterol due to reduced VLDL and LDL cholesterol levels, whereas overexpression of apoE alone did not reduce plasma cholesterol levels. When the LDLR and apoE were coexpressed in this model, the effects on plasma cholesterol levels were no greater than with expression of the LDLR alone. However, coexpression did result in a substantial increase in large apoE-rich HDL particles. In addition, although the combination of cholesterol reduction and apoE expression significantly reduced atherosclerosis, its effects were no greater than with expression of the LDLR or apoE alone. In summary, in this LDLR-deficient mouse model fed a Western-type diet, there was no evidence of an additive effect of expression of the LDLR and apoE on cholesterol reduction or atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369802

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

Review 1.  Liver-directed gene therapy for dyslipidemia and diabetes.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

2.  The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha.

Authors:  Michihisa Umetani; Pritam Ghosh; Tomonori Ishikawa; Junko Umetani; Mohamed Ahmed; Chieko Mineo; Philip W Shaul
Journal:  Cell Metab       Date:  2014-06-19       Impact factor: 27.287

3.  ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

Review 4.  Inhibition and regression of atherosclerotic lesions.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

5.  Gene Therapy Targeting LDL Cholesterol but not HDL Cholesterol Induces Regression of Advanced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia.

Authors:  Rongying Li; Hsu Chao; Kerry W S Ko; Shelley Cormier; Carrie Dieker; Elie A Nour; Shining Wang; Lawrence Chan; Kazuhiro Oka
Journal:  J Genet Syndr Gene Ther       Date:  2011-09-28

6.  Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice.

Authors:  Florian Willecke; Chujun Yuan; Kazuhiro Oka; Lawrence Chan; Yunying Hu; Shelley Barnhart; Karin E Bornfeldt; Ira J Goldberg; Edward A Fisher
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 7.  Emerging roles of low-density lipoprotein in the development and treatment of breast cancer.

Authors:  Xuefeng Guan; Zhuo Liu; Zhen Zhao; Xuefeng Zhang; Siteng Tao; Bao Yuan; Jiabao Zhang; Dawei Wang; Qing Liu; Yu Ding
Journal:  Lipids Health Dis       Date:  2019-06-10       Impact factor: 3.876

8.  Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State.

Authors:  Georgios Louloudis; Samuele Ambrosini; Francesco Paneni; Giovanni G Camici; Dietmar Benke; Jan Klohs
Journal:  Front Cardiovasc Med       Date:  2021-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.